[Corrections] Correction to Lancet Oncol 2017; 18: 917–28

Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol 2017; 18: 917–28—In this Article, difference values representing the proportion of patients achieving pathological complete response between groups should have been listed without % signs. Additionally, the following sentence should have read "The treatment outcome difference was −0·03 (95% CI −0·11 to 0·05), with the 95% CI falling within the prespecified ±0·15 equivalence margin." These corrections have been made to the online version as of Sept 1, 2017.

http://ift.tt/2gvZvji